author-photo

Olena Werner

Novartis

11

Papers

39

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.

2020
Show All
- Source
- Cite
- Save
Citations (1)
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

2020 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

2019 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (15)
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
SERIOUS ADVERSE EVENTS AMONG OLDER PATIENTS IN THE ALTTO TRIAL

2019 Journal of Geriatric Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)